3-month paliperidone palmitate (Invega Trinza®)
Paliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication.
FDA-Approved Indication
Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months.
Dosage
The dose of 3-month paliperidone palmitate (Invega Trinza®) will depend on the last dose of 1-month paliperidone palmitate extended-release (Invega Sustenna) that the patient was on, as follows:
| Last dose of 1-month paliperidone palmitate |
Starting dose of 3-month paliperidone palmitate |
| 78 mg | 273 mg |
| 117 mg | 410 mg |
| 156 mg | 546 mg |
| 234 mg | 819 mg |
Dosage forms and strengths
Extended-release injectable suspension: 273 mg, 410 mg, 546 mg, 819 mg
Prescribing Information
It is extremely important that prescriber’s review the full prescribing information before prescribing 3-month paliperidone palmitate (Invega Trinza)
